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Background. Concerns relating to increased use of psychotropic medication contrast with those of under-treatment and
under-recognition of common mental disorders in children and young people (CYP) across developed countries. Little is
known about the indications recorded for antidepressant prescribing in primary care in CYP.
Method. This was an electronic cohort study of routinely collected primary-care data from a population of 1.9 million,
Wales, UK. Poisson regression was undertaken to model adjusted counts of recorded depression symptoms, diagnoses
and antidepressant prescriptions. Associated indications were explored.
Results. 3 58 383 registered patients aged 6–18 years between 1 January 2003 and 31 December 2013 provided a total of
19 20 338 person-years of follow-up. The adjusted incidence of antidepressant prescribing increased signiﬁcantly [inci-
dence rate ratio (IRR) for 2013 = 1.28], mainly in older adolescents. The majority of new antidepressant prescriptions
were for citalopram. Recorded depression diagnoses showed a steady decline (IRR = 0.72) while depression symptoms
(IRR = 2.41) increased. Just over half of new antidepressant prescriptions were associated with depression (diagnosis
or symptoms). Other antidepressant prescribing, largely unlicensed, was associated with diagnoses such as anxiety
and pain.
Conclusion. Antidepressant prescribing is increasing in CYP while recorded depression diagnoses decline. Unlicensed
citalopram prescribing occurs outside current guidelines, despite its known toxicity in overdose. Unlicensed antidepres-
sant prescribing is associated with a wide range of diagnoses, and while accepted practice, is often not supported by
safety and efﬁcacy studies. New strategies to implement current guidance for the management of depression in CYP
are required.
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Introduction
The recognition and management of mental disorders
in children and young people (CYP) is increasingly a
source of controversy. There are concerns that mental
disorders in CYP are not recognized and are under-
treated (Department of Health, 2012, 2015) which are
in contrast to those in relation to the medicalization of
unhappiness and normal human experience with result-
ing over-diagnosis and over-treatment (Watts, 2012;
APA, 2013; Dowrick & Frances, 2013; Gaughwin, 2014).
The former is supported by evidence that their conditions
are often not appropriately recognized (Fitzpatrick et al.
2012) and that when they are recognized there is a
serious lack of treatment resources (Royal College of
Psychiatrists, 2015). In addition, studies have demon-
strated that antidepressants in particular have been
underused in CYP who have taken their own lives
(Windfuhr et al. 2008; Dudley et al. 2010). The latter is
supported by the already increasing use of psychotropic
medication in CYP in the United States (Olfson et al.
2002) Europe (Steinhausen & Bisgaard, 2014) and the
UK (Middleton et al. 2001; Rani et al. 2008; Lockhart &
Guthrie, 2011; John et al. 2015) but may be more of an
issue for the United States due to differing diagnostic
practices (James et al. 2014). Nonetheless mental health
andwell-being are of increasing public health importance
worldwide, with depression estimated to be the leading
cause of disease burden by 2030 (WHO, 2004). Studies
have shown that depression is common in adolescents
with at least one-half of those diagnosed going on to
have recurrent depression in adulthood (Kessler et al.
2001). The adverse impact of mental health disorders
on life outcomes such as educational under-achievement,
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employment, (Kessler et al. 1995) and teenage pregnancy
(Kessler et al. 1997) plus the serious disruptions to indivi-
duals’ lives and those of their families has resulted in
calls for increased outreach services and early interven-
tion (WHO, 2004).
The most recent data analysed in the UK, up to 2009,
has demonstrated an increase in all new antidepressant
prescriptions across all age groups (Middleton et al.
2001; Lockhart & Guthrie, 2011; Wijlaars et al. 2012).
Kendrick et al. (2015a) examined antidepressant pre-
scribing in those with non-psychotic depression symp-
toms or diagnoses only across all age groups and found
prescribing rates for patients with incident depression
fell following the introduction of depression guidelines
for adults (NICE, 2004) and the Quality and Outcomes
Framework (BMA and NHS Employers, 2006) while
rates for recurrent depression increased. A review of
the use of selective serotonin reuptake inhibitors
(SSRIs) in childhood in 2004 concluded that ﬂuoxetine
was the only one with a favourable risk/beneﬁt
proﬁle (Whittington et al. 2004) and thus it is the only
antidepressant licensed for use in CYP (NICE, 2005).
Following this review the National Institute for
Health and Care Excellence (NICE) published clinical
guideline 28 (NICE, 2005) in 2005 (updated March
2015), recommending that the ﬁrst-line treatment for
moderate to severe depression in CYP is psychological
therapies. In general, antidepressant medication should
be offered only in combination with psychological ther-
apies. If ﬂuoxetine is unsuccessful after an adequate
trial at adequate dosages and the depression is sufﬁ-
ciently severe to justify the trial of another antidepres-
sant, NICE recommends citalopram or sertraline as
second-line treatments. However, this is required to
be logged as unlicensed use. A study using GP practice
records up to 2009 demonstrated that citalopram (not
ﬂuoxetine) represented the highest annual rate of
change in new prescribing for young people in
England (Wijlaars et al. 2012).
Primary care is often the ﬁrst point of contact for
individuals seeking help for mental health problems.
Previous studies utilizing routine data have shown
an increase in recording of symptoms alongside a cor-
responding decrease in the recording of diagnoses for
anxiety and depression in adults (Rait et al. 2009;
Walters et al. 2012; Kendrick et al. 2015a) and CYP
(Wijlaars et al. 2012; John et al. 2015). The decrease in
recording of depression diagnoses may be partially
attributable to cautious diagnostic behaviour by GPs
following the controversy over the safety of antidepres-
sant use in CYP in 2003 [Committee of Safety of
Medicines (CSM), 2003] and strategic labelling of de-
pression in order to maintain adherence with Quality
Outcomes Framework (QOF) guidelines (Mitchell
et al. 2011; Wijlaars et al. 2012), a pay-for-performance
indicator in primary care which includes assessment
of depression diagnoses. There is only one previous
UK study using 2001 data that attempts to identify
the indications associated with the prescription of anti-
depressants for CYP (Murray et al. 2004) using routine-
ly collected primary-care data. This was prior to the
2003 CSM advice, changes in GP recording behaviour
and QOF. Given the concerns about over-
medicalization of symptoms and that the increase in
new prescriptions of antidepressants for CYP is not
reﬂected by a comparative trend in depression diagno-
sis, a better understanding of the context in which anti-
depressant use is initiated in this population is
warranted. Additionally, an examination of more re-
cent trends in the incidence of the prescribing of anti-
depressants by age group, particularly ﬂuoxetine and
citalopram is required.
Aims
The aim of this study is to examine recent trends and
indications for primary-care prescribing of antidepres-
sants in children and young people (CYP).
Method
Design
A retrospective electronic cohort study was conducted
utilizing the Secure Anonymized Information Linkage
System (SAIL Databank; http://www.saildatabank.
com) developed in the Health Information Research
Unit (HIRU) in Swansea University Medical School.
Data source
The SAIL Databank is an expanding data repository
(over 2 billion records) of anonymized person-based
linkable data to support research. SAIL was estab-
lished by HIRU at Swansea University in 2004 and
forms part of the Health e-Research Collaboration
UK (HeRC UK), led by the Medical Research Council
(MRC) and based in the Centre for the Improvement
of Population Health through e-Records Research
(CIPHER). CIPHER is a UK Clinical Research
Collaboration (UKCRC) Public Health Research Centre
of Excellence set within the Farr Institute at Swansea
University Medical School. Policies, structures and con-
trols are in place to protect patient conﬁdentiality. A
high-performance computing infrastructure and a reli-
able matching, anonymization and encryption process
in conjunction with the NHS Wales Informatics
Service uses a split ﬁle approach to import data into
SAIL. This ensures anonymization and conﬁdentiality,
while maintaining the facility of data linkage at the
level of the individual to any of the datasets housed
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in SAIL, such as general practice records, hospital
admissions and demographic information (Ford et al.
2009; Lyons et al. 2009).
For the purpose of this study data were utilized from
several datasets linked at the patient level:
• The Welsh Demographic Service (WDS) is a core
dataset available within the SAIL Databank and
part of a set of services to manage administrative in-
formation (demographic data) for NHS patients in
Wales. The WDS was introduced early in 2009 re-
placing a similar service known as the NHS Wales
Administrative Register (NHS AR). The WDS is a
register of all individuals who have at some point
in time been registered with a GP in Wales or
required some form of NHS healthcare provision
in Wales.
• The General Practice Database (GPD) contains at-
tendance and clinical information for all general prac-
tice interactions including symptoms, investigations,
diagnoses and prescribed medication. Currently,
regularly updated data are collected from 195 SAIL
practices (out of 474 in Wales) covering a total popu-
lation of over 1.9 million.
• Small-area deprivation scores were taken from the
Welsh Index of Multiple Deprivation 2011 (http://
gov.wales/statistics-and-research/welsh-index-mul
tiple-deprivation/technical-information/?lang=en).
This index is derived from eight separate domains of
deprivation including income, employment and
education. This dataset assigns a deprivation score
to all 1909 Lower Layer Super Output Areas
(LSOAs) in Wales, with an average population of
1500 people (range: 998–4402). LSOAs were ranked
by deprivation score and divided into quintiles of
equal counts.
Study population and setting
Individuals aged from 6 to 18 years between 1 January
2003 and 31 December 2013 were identiﬁed in the
WDS. Due to the small number of prescriptions in
those aged 0–5 years (<50) this age group was
excluded. Data collection began either 6 months from
GP registration or at study onset whichever was the
later. Data collection ended at the end of registration
with a SAIL GP, date of death, 19th birthday or the
study end date, whichever was sooner. Individuals
supplying a minimum of 6 months of data based on
these criteria (and therefore registered with a SAIL
GP for a minimum of 1 year) were included in the co-
hort. Each individual could supply more than one per-
iod of data provided the above criteria were met. For
each year, data were collected between the start and
end dates identiﬁed when constructing the original
cohort or, between 1 January and 31 December if an
individual’s period of data collection extended beyond
these dates.
Measures
We queried the primary-care database using db2 struc-
tured query language (SQL), implementing Read
Codes versions 2 and 3 (5-byte set). Read codes, a hier-
archical nomenclature, are used in primary care to re-
cord clinical summary information. The Read codes
and algorithms being used to identify symptoms or
diagnoses of depression have been developed and uti-
lized in previous research and excluded those for
psychosis (Supplementary Table S1) (Kessler et al.
1997; Whittington et al. 2004; Wijlaars et al. 2012;
John et al. 2016). Antidepressant prescriptions were
divided into SSRIs, tricyclic antidepressants (TCADs)
and other antidepressants (Supplementary Table S2)
as listed in the British National Formulary and in use
at any time during the study period.
Individuals with an incident or prevalent anti-
depressant prescription or, incident, prevalent or re-
current diagnosis of depression or symptom of
depression were identiﬁed in each year of the cohort.
Mixed anxiety and depression is reported elsewhere
( John et al. 2015). An incident episode was deﬁned as
no record of the given subtype (antidepressant pre-
scription or depression diagnosis or depression symp-
tom) in the previous 12 months. Participants could
have more than one episode recorded across the
study period as long a period of at least 12 months
existed between entries within that subtype, in keeping
with previous studies (Rait et al. 2009; Walters et al.
2012; Wijlaars et al. 2012; John et al. 2015). Similarly
participants could have more than one subtype
recorded within a given year, e.g. a depression diagno-
sis and antidepressant prescription, again as long a
period of at least 12 months existed between entries
within that subtype. An annual prevalent episode
was deﬁned as an individual with any record of the
given subtype (antidepressant prescription or depres-
sion diagnosis or depression symptom) in a target
year (John et al. 2016). An annual recurrent episode
was deﬁned as the ﬁrst record in a given year of a
given subtype where a record of that subtype exists
previously in that individuals GP record.
We conducted time trend analyses to determine
whether signiﬁcant changes in rates of recorded de-
pression diagnosis or symptom codes occurred follow-
ing the introduction of NICE guidance in 2004 and
2005 and the introduction of QOF indicators for de-
pression in quarterly blocks, as conducted in previous
literature (Kendrick et al. 2015a). We also conducted a
time trend analysis by quarter in the 24 months prior
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to the United States Food and Drug Administration
(August 2011), Safety Communication (United States
Food and Drug Administration) followed by a UK
Government Drug Safety Update (December 2011),
(Medicines and Healthcare products Regulatory
Agency, 2011) that considered citalopram was asso-
ciated with dose-dependent QT interval prolongation
of antidepressant subtype to assess any change in pre-
scribing of type of antidepressant.
Routine data does not explicitly link medication pre-
scription with a diagnosis. The records of individuals
with a new antidepressant prescription were further
analysed to identify the indication for which the medi-
cation was prescribed. GP records were reviewed for 1
year before and 6 months after the initial incident pre-
scription date for depression and anxiety diagnoses
(including mixed anxiety and depression) and symp-
toms before searching for other possible indications.
After depression and anxiety, the indications searched
were: pain, enuresis, attention deﬁcit hyperactivity
disorder, conduct disorders, autism, headaches, mi-
graine prophylaxis sleep problems, other codes of
interest (including tearfulness and psychosis), irritable
bowel syndrome, stress, phobias and obsessive disor-
ders, dissociative disorders and eating disorders
(Gardarsdottir et al. 2007). If an individual with a
new antidepressant prescription had a diagnosis or
symptom of depression, anxiety or mixed anxiety de-
pression recorded it was assumed that this was the in-
dication for which the medication was prescribed and
they were not examined for any further diagnoses.
Age, gender and deprivation quintile data were col-
lected based upon the onset of data collection for each
year. Age was categorized into three groups; 6–10, 11–
14 and 15–18 years.
Statistical analysis
Annual incidence rates were calculated using person-
years at risk (PYAR) as the denominator. Annual
prevalence rates were also calculated using PYAR as
a denominator. This is a more appropriate denomin-
ator than the number of registered cases because each
individual’s duration of follow-up was not ﬁxed
(John et al. 2016). Poisson regression was undertaken
to model the counts of both recorded depression symp-
toms, diagnoses and antidepressant prescriptions, as a
function of year of diagnosis, gender, age group and
deprivation. The signiﬁcance of variables in the
Poisson regression modelling was assessed using
Wald tests. Robust standard errors for the estimated in-
cidence rate ratios (IRRs) were used to account for clus-
tering within practices. Analysis was conducted using
SPSS v. 20 (IBM Corp., USA; syntax available on
request).
Quarterly rates were calculated using person-
quarters at risk as a denominator, in keeping with pre-
vious research of this type (Kendrick et al. 2015b). An
interrupted time-series analysis was undertaken to as-
sess the signiﬁcance of changes based on quarterly
data using segmented regression (Wagner et al. 2002).
This analysis divides the time series into two periods
before and after a given event to assess whether
there was a signiﬁcant step change or change in
slope of the line following an event (futher details
are available in Kendrick et al. 2015b). An autoregres-
sive, integrated moving-average time-series model
was implemented accounting for autocorrelation.
Ethical statement
Approval was granted from the HIRU Information
Governance Review Panel (IGRP), an independent
body consisting of a range of government, regulatory
and professional agencies, which oversees study
approvals in line with ethical permissions already
granted to the analysis of data in the SAIL Databank
(Lyons et al. 2009; Ford et al. 2009). Approval number
0242.
Results
Study population
A total of 3 58 383 individuals aged 6–18 years between
1 January 2003 and 31 December 2013 contributed 19
20 338 person-years of data. The mean follow-up time
was 5.36 years.
Trends in the incidence of antidepressant prescribing
over time
A total of 10 037 (2.8%) individuals received 10 650 in-
cident antidepressant prescriptions during the study
period. Of these 10 650 prescriptions, 9754 [91.6%,
95% conﬁdence interval (CI) 91.1–92.1] represent the
ﬁrst ever record of such a prescription in the GP
data. Of those incident prescriptions that had 51
year of GP follow-up data (n = 4775), 3298 received
52 prescriptions (69.1%, 95% CI 67.8–70.4) of which
1809 (37.9%, 95% CI 36.5–39.3) received 55 prescrip-
tions in the subsequent year.
The crude incidence of antidepressant prescribing
showed an initial decline (Fig. 1) from 5.26 to 4.36
cases/1000 PYAR from 2003 to 2005 (IRR 0.73, 95%
CI 0.66–0.80). However, the rate of prescribing began
to increase from 2005 onwards to 7.69 cases/1000
PYAR in 2013. Adjusted IRRs for year, gender, age
group and deprivation are shown in Table 1. The pre-
scription rate was lower between 2004 and 2008 com-
pared to the baseline year 2003 but increased
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signiﬁcantly between 2011 and 2013 (2013: IRR 1.28,
95% CI 1.18–1.40). The prescription rate was higher
in females (IRR 2.72, 95% CI 2.60–2.85) and highest
in the 15–18 years age group (Fig. 2), with a smaller in-
crease in 11- to 14-year-olds.
SSRIs represented the most frequently prescribed
antidepressant across the study period. Citalopram, al-
though unlicensed in this age group, was the most
popular SSRI, accounting for around 40% of all new
prescriptions, followed by ﬂuoxetine at over one-third
(Fig. 3). Of the 4019 citalopram prescriptions issued
over the study period to those aged 6–18 years, <1%
were given to those aged 6–10 (n = 15), 3% were
given to those aged 11–14 (n = 134) and 96% (n = 3870)
were given to those aged 15–18. Of the total citalo-
pram prescriptions 29% (n = 1162) were given to
18-year-olds. Prescriptions for other SSRIs, TCAs and
other antidepressants remained at a low rate.
A non-signiﬁcant increasing trend in incident anti-
depressant prescriptions followed the issue of 2004
NICE guidance (Supplementary Fig. S1, Supplementary
Table S3). Similarly a non-signiﬁcant increasing trend in
prescriptionsofﬂuoxetine in 15- to 18-year-olds alongside
a decrease in rate of prescribingof citalopramwas evident
prior to the 2011 safety warnings relating to citalopram.
This non-signiﬁcant decrease in rates of citalopram pre-
scriptions continued following the 2011 warnings
(Supplementary Figure S2; Supplementary Table S4).
The annual prevalence of antidepressant prescrip-
tions and depression diagnoses and symptoms are
shown in Supplementary Table S5. For all subtypes
(prescriptions, diagnosis and symptoms), the majority
of records represent incident as opposed to prevalent
cases.
Time trends in incident and recurrent diagnosis of
depression and depressive symptoms
There were 4060 new diagnoses of depression (3860
individuals) and 8477 new cases of depressive symp-
toms (7931 individuals) during the study period.
New diagnoses of depression (Fig. 1) decreased sign-
iﬁcantly from 2.35 cases/1000 PYAR in 2003 to 1.91
cases in 2013 (IRR 0.72, 95% CI 0.62–0.83). Recording
of depression symptoms more than doubled from
2.48 to 6.59 cases/1000 person-years (IRR 2.41, 95%
CI 2.16–2.68) over the study period (Table 1).
Recurrent diagnoses of depression (Fig. 1) decreased
signiﬁcantly over time from 0.71 to 0.36 cases/1000
PYAR over the study period (IRR 0.74, 95% CI 0.20–
0.74). Recording of recurrent symptoms of depression
signiﬁcantly increased from 0.55 to 2.24 cases/1000
PYAR at over the study period (IRR 3.60, 95% CI
2.81–4.61) (Supplementary Table S6).
An increasing trend in depression symptoms along-
side a decrease in diagnoses is evident (Supplementary
Fig. S3) in quarterly time points over the 24 months ei-
ther side of the issue of 2006 QOF performance indica-
tors for depression. However, this was not statistically
signiﬁcant (Supplementary Table S7). Similarly a non-
Fig. 1. Rate of incident and recurrent depression diagnosis and symptoms and incident antidepressant prescriptions over
time.
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Table 1. Incidence rate ratios for depression diagnosis, symptoms and antidepressant prescription
Depression diagnosis Depression symptoms Antidepressant prescriptions
Variable Events IRR (95% CI)a Events IRR (95% CI)a Events IRR (95% CI)a
Gender
Male 966 Reference 2210 Reference 2976 Reference
Female 3094 3.38 (3.14–3.64) 6267 3.00 (2.86–3.15) 7674 2.72 (2.60–2.85)
Age group, yr
6–10 28 Reference 191 Reference 178 Reference
11–14 432 18.40 (12.01–28.00) 1636 9.83 (8.30–11.60) 926 5.97 (4.69–7.60)
15–18 3600 170.34 (113.04–256.69) 6650 43.8 (37.34–51.5) 9546 68.3 (54.5–85.5)
Deprivationb
1 1156 Reference 2210 Reference 3260 Reference
2 776 1.17 (1.04–1.32) 1632 1.19 (1.11–1.27) 2177 1.14 (1.06–1.23)
3 726 1.25 (1.12–1.40) 1586 1.27 (1.19–1.36) 2097 1.25 (1.17–1.34)
4 542 1.53 (1.39–1.69) 1200 1.52 (1.42–1.64) 1524 1.50 (1.40–1.62)
5 540 1.99 (1.81–2.19) 1199 1.75 (1.65–1.86) 1579 1.94 (1.81–2.07)
Year
2003 419 Reference 441 Reference 937 Reference
2004 456 0.91 (0.81–1.02) 625 1.21 (1.10–1.34) 945 0.84 (0.76–0.93)
2005 465 0.92 (0.82–1.03) 636 1.2 (1.06–1.37) 836 0.73 (0.66–0.80)
2006 425 0.83 (0.73–0.94) 772 1.46 (1.34–1.59) 861 0.75 (0.68–0.83)
2007 402 0.79 (0.69–0.90) 750 1.43 (1.27–1.60) 928 0.81 (0.74–0.88)
2008 357 0.70 (0.60–0.82) 801 1.52 (1.40–1.65) 958 0.83 (0.77–0.90)
2009 379 0.75 (0.66–0.86) 887 1.71 (1.54–1.89) 1033 0.91 (0.81–1.02)
2010 332 0.68 (0.56–0.83) 925 1.85 (1.69–2.01) 1082 0.99 (0.91–1.08)
2011 341 0.76 (0.67–0.85) 897 1.94 (1.76–2.13) 1134 1.12 (1.03–1.22)
2012 258 0.65 (0.58–0.74) 962 2.37 (2.16–2.60) 1025 1.15 (1.04–1.28)
2013 226 0.72 (0.62–0.83) 781 2.41 (2.16–2.68) 911 1.28 (1.18–1.40)
IRR, Incidence rate ratio; CI, conﬁdence interval.
a Adjusted for calendar year, gender, age group and deprivation.
b Deprivation: 1 = least deprived; 5 =most deprived.
Fig. 2. Incidence of antidepressant prescription by age group over time.
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signiﬁcant increase in the rate of incident and recurrent
depression diagnoses and symptoms can be seen fol-
lowing the 2008 recession in 15- to 18-year-olds
(Supplementary Fig. S4, Supplementary Table S8).
Age, gender and deprivation
A record of a depression diagnosis, depression symp-
tom(s) and new antidepressant prescriptions were ap-
proximately three times more likely in females
(diagnosis: IRR 3.38, 95% CI 3.14–3.64; symptoms:
IRR 3.00, 95% CI 2.86–3.15; antidepressants: IRR 2.72,
95% CI 2.60–2.85) compared to males (Table 1). This
gender difference became more apparent with increas-
ing age. In those aged 6–10 years the female: male ratio
for depression diagnosis, symptoms and antidepres-
sant prescriptions were 0.56:1, 1.01:1 and 0.63:1, com-
pared to the female:male ratios of 3.32:1, 2.95:1 and
2.76:1, respectively, in those aged 15–18 years. A re-
cord of a depression diagnosis, depression symptom
(s) and new antidepressant prescriptions were approxi-
mately twice as common in the most deprived com-
pared to the least deprived areas (diagnosis: IRR
1.99, 95% CI 1.81–2.19; symptoms: IRR 1.75, 95% CI
1.65–1.86; antidepressants: IRR 1.94, 95% CI 1.81–
2.07) (Table 1).
In keeping with recording of incident depression,
recording of both recurrent depression diagnoses and
symptoms were more than four times as high in
females than males (diagnosis: IRR 4.45, 95% CI
3.85–5.14; symptoms: IRR 4.16, 95% CI 3.76–4.60).
Recording of both recurrent depression diagnoses
was also signiﬁcantly higher in the most deprived
compared with the least deprived areas (diagnosis:
IRR 1.74, 95% CI 1.47–2.05; symptoms: IRR 2.02, 95%
CI 1.78–2.31) (Supplementary Table S6).
Indications for antidepressant prescriptions
The incidence rates of antidepressant prescriptions by
indication are shown in Fig. 4. The biggest single indi-
cation for new antidepressant prescriptions was depres-
sion (diagnoses and symptoms), which was associated
with over one-half of new prescriptions. New prescrip-
tions associated with depression increased from 2.77
cases/1000 person-years in 2003 to 3.86/1000 person-
years in 2013. New prescriptions associated with anx-
iety were less frequent but increased from 0.28 in
2003 to 0.74 cases/1000 person-years in 2013. The inci-
dence of antidepressant prescriptions associated with
physical pain also increased over the study period
from 0.57/1000 person-years in 2003 to 1.47/1000
person-years in 2013. No other single indication
reached sufﬁcient numbers to be shown separately,
for example obsessive compulsive disorder was
recorded in total <20 times/year over the study period.
As a group, prescriptions associated with other indica-
tions changed little from 0.33 to 0.35 cases/1000 person-
years. Overall, the indication for which an antidepres-
sant was prescribed could not be found for 1793
(16.8%, 95% CI 16.1–17.5) of new prescriptions. New
prescriptions for which no indication could be iden-
tiﬁed showed an initial decline from 1.32 to 0.66
cases/1000 person-years from 2003 to 2006. However,
the incidence began to rise again from 2007 onwards
reaching 1.27 cases/1000 person-years in 2013. This pat-
tern was reﬂective of the overall trend for SSRIs over
the study period.
Fig. 3. Incidence of antidepressant prescriptions by antidepressant type over time.
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Discussion
Main ﬁndings
The incidence of antidepressant prescriptions for CYP
initially decreased between 2003 and 2005 then stead-
ily increased over the study period to the highest inci-
dence in 2013. This lends credence to suggestions that
concerns in 2003 (Committee of Safety of Medicines,
2003) over the safety of antidepressant use in CYP
waned (Wijlaars et al. 2012). Since 2003, the increase
in recording of depressive symptoms in CYP has con-
tinued throughout the study period although the
recording of a diagnosis of depression has shown a
small but steady decline. Unlicensed antidepressant
prescribing was associated with a range of diagnoses
as well as for depression, such as anxiety and pain.
Potential indications for antidepressant therapy were
found for approximately 83% of new prescriptions.
The increase in prescribing of antidepressants over
time is mainly seen in those aged 15–18 years rather
than younger age groups. No increase in antidepres-
sant prescribing was found in 6- to 10-year-olds.
Citalopram is the most frequently prescribed anti-
depressant across the study period despite ﬂuoxetine
being recommended as ﬁrst-line treatment and the
only antidepressant licensed for use in this age group
since it is the only SSRI with a favourable risk/beneﬁt
proﬁle (Whittington et al. 2004; NICE, 2005, updated
March 2015). However, ﬂuoxetine does appear to
have increased in popularity from 2009 onwards,
with its incidence at a similar level to citalopram by
2013. This is still not consistent with current NICE
guidance and advice in the BNF for children. The de-
cline in citalopram prescribing seen from 2011 may
have followed a United States Food and Drug
Administration (August 2011), Safety Communication
(United States Food and Drug Administration) fol-
lowed by a UK Government Drug Safety Update
(December 2011), (Medicines and Healthcare products
Regulatory Agency, 2011) that considered citalopram
was associated with dose dependent QT interval pro-
longation. Although we found a downward trend we
did not ﬁnd signiﬁcant evidence for this. Where data
were available, it appears that around 69% of new pre-
scriptions of antidepressants are associated with at
least one other prescription being issued in the subse-
quent year.
Strengths and limitations
The main strength of this study is the large population
sample size of all children and young people in Wales
and 11 years of follow-up. There is no reason to believe
the results would differ for the entire population of UK
children.
The results of the current study reﬂect trends in the
recording of presentations to primary care, and the rec-
ognition and treatment by GPs. All prescriptions
issued in primary care are recorded within the GPD,
but we have no available method of ascertaining
from the SAIL Databank if they were dispensed or
taken. The incidence rates for diagnoses and symptoms
presented are likely to be an underestimate of the true
incidence in the community as a whole since those
who do not present to their GP, or those with whom
symptoms are discussed but not recorded, will be
missed by the use of routinely collected data. This is
a common feature of all database studies, (Rait et al.
2009; Wijlaars et al. 2012; Walters et al. 2012).
Fig. 4. New antidepressant prescriptions by indication over time.
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Although we explored a more extensive list of indi-
cations for which an antidepressant may be prescribed
than previously reported, (Murray et al. 2004) the indi-
cation for which a medication is prescribed is not expli-
citly recorded in routinely collected primary-care data.
Thus the indications can only be inferred and not con-
clusively determined. Analyses reported relating to in-
dication are, in essence, a measure of coding behaviour
rather than true indications for prescribing. Only those
patients with relevant Read codes in their patient re-
cord were detected. The method used will give an in-
dication of trends over time but may have resulted in
an inﬂated number of individuals for whom no indica-
tion could be found, particularly where a historical re-
cord was only made once or where an individual was
not registered with a SAIL practice at the time when a
diagnosis was recorded. This is a common limitation of
all studies of this type (Murray et al. 2004). It is possible
that GPs consider that the prescribing of an antidepres-
sant implies the diagnosis.
The results of this analysis should not be used to
make comparisons of rates of prescribing found across
different study populations such as those in the THIN
database (Whittington et al. 2004). This is because these
studies provide a crude non-standardized estimate of
the incidence of antidepressant prescribing without
taking into account any differences between study
populations based on age, gender and deprivation
that are known to be associated with levels of child-
hood depression. Our ﬁndings may be inﬂuenced by
a period effect as the CYP investigated age through
the study period. The large proportion of individuals
compared to events (e.g. 4060 new depression diagnoses
compared to 3860 individuals) and prescriptions (e.g.
10 037 individuals received 9754 incident antidepressant
prescriptions) suggests that largely different cohorts of
children were assessed across the study period.
It would have been preferable to replicate previous
work and examine rates of treated incident, ﬁrst ever
and recurrent depression in relation to issuing of
NICE guidance for depression in 2004 and 2005 as
done by Kendrick et al. (2015b) in adults. However,
the number of cases of CYP are lower. This smaller
sample size combined with the impact of only examin-
ing those with adequate follow-up data to determine
treatment meant that there were not sufﬁcient numbers
to draw meaningful conclusions. Incident antidepres-
sant prescriptions were examined as an alternative.
A further limitation is the lack of information regard-
ing whether and what interventions have been
received at secondary and tertiary mental healthcare
levels for children and adolescents with depression,
i.e. where ﬂuoxetine or citalopram has been initiated
at a secondary care level or access to psychological
therapies.
The Read codes and algorithms employed in this
study have been previously examined against adult
survey data (John et al. 2016) giving a distinct advan-
tage over other studies of this type where an examin-
ation of real-world recording behaviour has not been
possible, (Kessler et al. 1997; Whittington et al. 2004;
Wijlaars et al. 2012). Further work is required to extend
this linkage of routinely collected data to survey data
collected on CYP.
Comparison with previous literature
This study adds to a growing literature demonstrating
an increase in psychotropic prescribing for CYP across
western cultures (Olfson et al. 2002; Dowrick &
Frances, 2013; Steinhausen & Bisgaard, 2014). We
found the percentage of the CYP population receiving
new prescriptions for antidepressants was in keeping
with the THIN study from 2009 (Wijlaars et al. 2012).
The results of this study support and extend previous
research demonstrating an increase in recording of de-
pressive symptoms and decrease in depression diagno-
ses over time (Whittington et al. 2004; NICE, 2005; Rait
et al. 2009; Walters et al. 2012; Wijlaars et al. 2012). In
keeping with previous research (Kendrick et al.
2015a), no signiﬁcant trend over time was found in
recording of depression diagnosis or symptoms when
analysing quarterly time points in the 24 months either
side of the 2006 QOF performance indicators for de-
pression or in relation to the 2008 recession in 15- to
18-year-olds. Similarly the non-signiﬁcant increasing
trend in incident antidepressant prescriptions seen fol-
lowing the issue of 2004 and 2005 NICE guidance is in
keeping with previous research (Kendrick et al. 2015b)
where no signiﬁcant change was found in both recur-
rent and overall episodes of depression treated with
antidepressants related to NICE guidance. The positive
results reported in this study refer to the number of in-
cident episodes of depression treated following the
issue of the guidance.
A previous study from 2001, prior to CSM advice,
found indications for around 70% of antidepressant pre-
scriptions, (Murray et al. 2004) and did not limit its ana-
lysis to new prescriptions. Pain, which accounted for
16% of new prescriptions in the current study, was not
examined. The comprehensive list of indications
employed in the current study has identiﬁed potential
indications for 83% of new prescriptions. Many of
these indications are unlicensed usage such as for pain.
In keeping with previous research, (Murray et al. 2004)
depression is the most commonly associated indication.
Implications
It may be useful to issue further guidance and support
to GPs in relation to indications for effective
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antidepressant prescribing and to promote the record-
ing of a diagnosis when issuing a prescription.
Tricyclic antidepressants rather than SSRIs are the
mainstay of neuropathic pharmacological pain treat-
ment and are considered to be ﬁrst-line drugs in
adult practice (Gregoire & Finley, 2013). They are
also used off-license in paediatrics, but without much
published evidence. A Cochrane review (Kaminski
et al. 2011) failed to support their effectiveness in treat-
ing CYP’s chronic pain. There are currently no pub-
lished guidelines for neuropathic pain in children
(Gregoire & Finley, 2013). Many GPs feel poorly
equipped to manage young people’s emotional distress
and feel there is a lack of clarity (Roberts et al. 2013).
There are no speciﬁc NICE guidelines available for
the management of anxiety in CYP. There are NICE
guidelines for anxiety (which relate principally to
adults; NICE, 2011), depression for CYP (which
includes mixed anxiety and depression; NICE, 2005,
updated 2015) and for the assessment and treatment
of social anxiety disorder (NICE, 2013). These all high-
light some considerations for the management of anx-
iety in CYP. Psychological therapies should be the ﬁrst
line of treatment. Pharmacotherapy should not be rou-
tinely offered to treat social anxiety disorder in young
people.
Additionally, strategies to improve the implementa-
tion of current guidance on the prescribing of antide-
pressants for depression in CYP should be adopted.
This could include adoption of programmes such as
Therapeutic identiﬁcation of depression in young peo-
ple (TIDY) which trains primary-care staff to differen-
tiate between emotional turmoil and depression and
to implement appropriate management strategies
(Kramer et al. 2012). A current focus should be the
use of citalopram rather than ﬂuoxetine as a ﬁrst line
treatment. The updated NICE guidance of 2015 recom-
mends that citalopram should only be prescribed if
ﬂuoxetine is unsuccessful or is not tolerated because
of side-effects and then only once advice is sought
from a senior child and adolescent psychiatrist. These
preferences in initiating antidepressant treatment also
warrant further research. It may be that GPs ﬁnd that
citalopram is better tolerated than ﬂuoxetine, or results
may simply reﬂect trends seen in adult populations
(Kessler et al. 2001) despite citalopram’s higher case-
fatality in overdose than other SSRIs (Hawton et al.
2010). It is also possible that the increase in citalopram
prescriptions is related to diagnoses other than depres-
sion, such as pain, prescribing for which appears to
have increased during the study period. The absence
of data regarding any interventions that may have
been received at secondary and tertiary mental health-
care levels make it difﬁcult to draw conclusions on
whether this trend is a reﬂection of GP preference or
of prescribing patterns initiated in secondary or ter-
tiary care. However, the rate of rejection of referrals
from primary-care to specialist mental health services
(Hinrichs et al. 2012) make it likely that treatment for
at least a proportion of individuals is exclusive to pri-
mary care. Further research is required to fully under-
stand the increasing trend in prescribing without an
associated indication. It may be that indications go be-
yond those studied here or that GPs are increasingly
choosing not to record depression in this population.
Over one-half of new antidepressant prescribing was
associated with a symptom or diagnosis of depression.
New prescriptions associated with depression (diagno-
sis and symptoms) increased over the study period.
This may reﬂect increased access to treatment and a
positive shift towards helping individuals with mental
disorder at a younger age or an increased tendency to
prescribe medication, particularly where psychological
or other treatment options are limited or not available
in primary care. This may be a particular problem in
more deprived areas where the incidence is nearly
double that in more afﬂuent areas. The increasing
levels of those receiving antidepressant treatment at
15–18 years of age also highlights the importance of
strengthening primary-care mental health care services
and supporting the transition to adult mental health
services, when required, given the persistence of ado-
lescent mental health problems into adulthood (Rait
et al. 2009).
A recent mixed methods study has found that gen-
eral practice referrals to Child and Adolescent Mental
Health Services (CAMHS) were three times more likely
to be rejected than referrals from all other sources com-
bined (Hinrichs et al. 2012). As a result, primary care
may remain the most common source of care for
CYP with mental health problems, independent of
whether a GP feels an individual requires more spe-
cialist support. Concerns remain over the safety of
many psychotropic medications for CYP, particularly
with regards to antidepressants where there has been
controversy regarding increased risk of suicidal idea-
tion and attempt following initiation of antidepressant
treatment (Committee of Safety of Medicines, 2003;
NICE, 2005). The uncertainty over whether those trea-
ted but not diagnosed are followed-up in line with
QOF guidance (Rait et al. 2009) makes the decrease in
recording of diagnoses alongside an increase in new
prescriptions a cause for concern in this age group.
Overall, the results suggest that GPs are increasingly
using non-speciﬁc symptom terms for recording de-
pressive mental disorders for CYP. This decrease in
recording of diagnoses may be partially attributable
to increasingly cautious diagnostic behaviour by GPs.
However this behaviour may also be in part due to
the revised QOF guidance, (Walters et al. 2012). Our
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results support the reports from GPs on the use of al-
ternative terms and strategic labelling of depression
to maintain adherence with guidelines (Rait et al. 2009).
Awareness that GPs are increasingly using non-
speciﬁc symptoms codes rather than formal diagnoses
for both adults, (Kessler et al. 1997; Wijlaars et al. 2012)
and CYP, (Whittington et al. 2004) across both England
and Wales is important for future research based on
routinely collected data. New research should examine
the impact of a formal diagnosis on patient care e.g. the
impact of treatment with or without a diagnosis on the
frequency of follow-up or long-term physical and
mental health. This is particularly relevant to CYP
where care received may have an enduring impact
into adulthood (Watts, 2012; Dowrick & Frances,
2013; Gaughwin, 2014).
Conclusion
This study contributes to a growing debate over in-
creasing rates of psychotropic medication prescriptions
in CYP. Antidepressant prescribing, associated with a
broad range of indications, is increasing in CYP
while the recorded diagnosis of depression shows a
steady decline. Citalopram continues to be prescribed
as an initial medication outside current guidelines.
Unlicensed antidepressant prescribing is associated
with a range of diagnoses other than depression,
such as anxiety and pain and, whilst accepted practice
included in prescribing guidance and advice, it is not
supported by safety and efﬁcacy studies, and could
be seen as contributing to the over medicalization of
CYP. It may be useful to issue guidance and support
to GPs in relation to indications for effective anti-
depressant prescribing and to promote the recording
of a diagnosis when issuing a prescription. New strat-
egies to implement current guidance for the manage-
ment of depression in this population are required.
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